You are here


May 26, 2016
Joint West Africa Research Group to Foster Biopreparedness

The West African Ebola outbreak highlighted gaps in global public health response and a lack of countermeasures. The DoD invested in a strategic initiative called the Join West Africa Research Group (JWARG) to leverage existing research platforms and relationships to improve biopreparedness in the region.

This new program is a collaboration between MHRP/WRAIR, Naval Medical Research...

May 18, 2016
HIV Vaccine Awareness Day: Building on the Success of RV144

As we mark HIV Vaccine Awareness Day, the research community is accelerating progress against HIV on all fronts.  We are coming together now more than ever—countries, organizations, prevention tools, research disciplines, and government agencies—in an unprecedented effort to control the global HIV/AIDS pandemic.

Today the NIH announced that the first large-scale clinical trial of an HIV...

May 18, 2016
Early-Capture HIV Study Allows for Characterization of Acute Infection Period

Acute HIV infection (AHI) contributes significantly to HIV transmission and may be important for intervention strategies seeking to reduce incidence and achieve a functional cure. In a study by the U.S. Military HIV Research Program (MHRP), Walter Reed Army Institute of Research, published today in The New England Journal of Medicine, scientists enrolled and intensively followed a cohort of...

March 24, 2016
World TB Day: MHRP Research Physician Examines Overlap in HIV and Tuberculosis

Tuberculosis recently overtook HIV as the top infectious disease killer world wide, and in 2015, 1 in 3 HIV deaths were due to TB. With a research background in multi-drug resistant tuberculosis, MHRP research physician Dr. Elizabeth Harausz is well positioned to battle these entangled epidemics.

In November, Dr. Harausz traveled to Geneva, Switzerland, to advise the World Health...

March 18, 2016
MHRP and Collaborators Presenting at Keystone Symposia HIV Vaccine and HIV Persistence Meetings

MHRP and collaborators are scheduled to speak and present at the 2016 Keystone Symposia HIV Vaccine and HIV Persistence meetings taking place March 20-24 in Olympic Valley, California.

Dr. Merlin Robb, MHRP’s clinical deputy director, is scheduled to speak during a plenary session focusing on immunologic correlates on March 21. Using examples gleaned from follow-up studies to MHRP’s...

March 16, 2016
Study Compares Hospitalization Rates Among HIV Controllers and Those With Medically Controlled HIV in Military Cohort

A new study published this week in the Journal of the International AIDS Society investigated hospitalization rates and reasons in the U.S. Military HIV Natural History Study (NHS), comparing patients with spontaneous virologic control of HIV to patients with medically controlled HIV.

“HIV controllers (HICs) maintain an undetectable viral load and high CD4 counts without antiretroviral...

March 8, 2016
Biomarkers of Disease Progression Appear to Differ in Sub-Saharan Population

Immune activation and inflammation help predict HIV disease progression and AIDS mortality in industrialized countries. These associations are different for a Sub-Saharan African population, according to an article published this week in the Journal of Acquired Immune Deficiency Syndromes.

The study assessed biomarkers of inflammation, microbial translocation, and cellular activation in...

February 22, 2016
MHRP Scientists and Collaborators Presenting at CROI 2016

MHRP and collaborators will give the following poster presentations at the annual Conference on Retroviruses and Opportunistic Infections (CROI) taking place February 22-25 in Boston: 

Tuesday, February 23 Western Blot Index for Estimating Recency of HIV Infection​  –Mark Manak (MHRP) Poster 515, Session P-M1, 2:45 p.m., Exhibit Hall A/B​

Virologic Failure is Uncommon After...

February 16, 2016
First-in-Human Phase 1 Clinical Trial of MERS Vaccine Begins

The Walter Reed Army Institute of Research (WRAIR) began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).

Though other vaccine candidates have previously been tested for use in camels, which are the suspected source of the coronavirus which causes MERS (MERS-CoV), this...

January 6, 2016
MHRP, WRAIR Begin New Phase 2 Clinical Trial of Ebola Vaccine Regimens

The Walter Reed Army Institute of Research (WRAIR) today announced the initiation of a Phase 2 clinical trial to evaluate the safety and immunogenicity of a prime-boost Ebola vaccine regimen in both healthy and HIV-infected study volunteers.

This study includes two vaccine candidates, Ad26.ZEBOV from Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson &...